A mini-review of c-Met as a potential therapeutic target in melanoma.

Autor: Al-U'datt DGF; Department of Pharmacology and Physiology, Faculty of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. Electronic address: doaa.al-udatt@umontreal.ca., Al-Husein BAA; Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. Electronic address: belalhusein@just.edu.jo., Qasaimeh GR; King Abdullah University Hospital-Jordan University of Science and Technology Irbid, Jordan.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2017 Apr; Vol. 88, pp. 194-202. Date of Electronic Publication: 2017 Jan 17.
DOI: 10.1016/j.biopha.2017.01.045
Abstrakt: Melanoma is the third highest rated cancer in prevalence. Surgery, radiotherapy and targeted/biological therapies in addition to chemotherapy are available options for management of this cancer. Met is an appealing target for management of this type of cancer, since it targets many cancer vital processors, such as angiogenesis, cell growth, scattering and differentiation. In this review, we provide an overview about pathway abnormalities associated with melanoma. We also provide a summary about the events involved in Met signaling and related signaling molecules. We also show the evidence of the importance of Met signaling pathway as a target in cancer management. We also summarize clinical evidence about the use of Met signaling in management of cancer and summarize available trials related to targeting Met in other cancers.
(Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: